Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Jillian L. Scavone, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020John A. Thompson, Anita M. Engh, Matthew J. Frigault et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 484
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Lisa Hang, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 416
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumorsAlbiruni RA Razak, Kyriakos P. Papadopoulos, James M. Cleary et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 117
Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.Georgina V. Long, F. Stephen Hodi, Reinhard Dummer et al.|Journal of Clinical Oncology|2016Cited by 110